Education
About Us
Working with TipRanks
Follow Us
Inventiva SA (FR:IVA)
:IVA
IVA Stock Chart & Stats
€3.45
-€0.02(-0.70%)
At close: 4:00 PM EST
€3.45
-€0.02(-0.70%)
Day’s Range― - ―
52-Week Range€2.00 - €5.55
Previous CloseN/A
Volume1.84K
Average Volume (3M)416.07K
Market Cap
€536.06M
Enterprise Value€219.67M
Total Cash (Recent Filing)€122.08M
Total Debt (Recent Filing)€57.13M
Price to Earnings (P/E)―
Beta0.62
Next Earnings
Apr 01, 2026EPS Estimate
-0.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.38
Shares Outstanding145,951,280
10 Day Avg. Volume620,713
30 Day Avg. Volume416,066
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)-1.22
Price to Sales (P/S)8.85
P/FCF Ratio-1.51
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€10.00Price Target Upside189.86% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe Phase 3 NATIV3 MASH trial is ongoing, with the main accelerated approval cohort and the exploratory/extension cohort fully enrolled, showing optimism for success on the composite endpoint of fibrosis and MASH resolution.
Financial StabilityCurrent proforma cash should provide OpEx runway to 1Q27, indicating strong financial stability.
Funding And Financial HealthIVA will book net proceeds of an additional €139M from their very recent US public offering of ADSs, which will support their financial health.
Bears Say
Financial LossesIVA reported a substantial net loss, with increased SG&A expenses primarily due to personnel costs related to share-based compensation.
Operational ChangesDue to the prioritization of the Ph3 lanifibranor MASH program, IVA conducted a significant reduction in workforce and paused all preclinical research.
Workforce ReductionInventiva is conducting a 50% reduction in force and pausing all preclinical research, indicating a strategic shift and potential short-term challenges.
Inventiva News
IVA FAQ
What was Inventiva SA’s price range in the past 12 months?
Inventiva SA lowest stock price was €2.00 and its highest was €5.55 in the past 12 months.
What is Inventiva SA’s market cap?
Inventiva SA’s market cap is €536.06M.
When is Inventiva SA’s upcoming earnings report date?
Inventiva SA’s upcoming earnings report date is Apr 01, 2026 which is in 114 days.
How were Inventiva SA’s earnings last quarter?
Inventiva SA released its earnings results on Sep 29, 2025. The company reported -€1.379 earnings per share for the quarter, missing the consensus estimate of -€0.546 by -€0.833.
Is Inventiva SA overvalued?
According to Wall Street analysts Inventiva SA’s price is currently Undervalued.
Does Inventiva SA pay dividends?
Inventiva SA does not currently pay dividends.
What is Inventiva SA’s EPS estimate?
Inventiva SA’s EPS estimate is -0.3.
How many shares outstanding does Inventiva SA have?
Inventiva SA has 145,951,280 shares outstanding.
What happened to Inventiva SA’s price movement after its last earnings report?
Inventiva SA reported an EPS of -€1.379 in its last earnings report, missing expectations of -€0.546. Following the earnings report the stock price went down -2.178%.
Which hedge fund is a major shareholder of Inventiva SA?
Currently, no hedge funds are holding shares in FR:IVA
Company Description
Inventiva SA
Inventiva (IVA) is a biopharmaceutical company headquartered in France, specializing in the development of innovative therapies for patients with unmet medical needs. The company focuses on two main therapeutic areas: fibrotic diseases and metabolic diseases, with a robust pipeline of drug candidates that leverage its proprietary platform. Inventiva is committed to advancing its research and development efforts to deliver transformative treatments that improve patients' quality of life.
IVA Stock 12 Month Forecast
Average Price Target
€10.00
▲(189.86% Upside)
Technical Analysis
Options Prices
Currently, No data available
---